Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 127, Issue 11, 2001, Pages 1319-1324

  Li, Daqing ^a   Shugert, Elizabeth ^a   Guo, Ming ^a   Bishop, Jeffrey S ^b   O'Malley Jr , Bert W ^b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Urigen Pharmaceuticals Inc   (United States)

^c Div Otolaryngol Hd and Neck Surg   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2; LIPID; POLYMER; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG FORMULATION; EXPERIMENTAL NEOPLASM; GENE THERAPY; HEAD CANCER; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MOUSE; MOUTH; NATURAL KILLER CELL; NECK CANCER; NONHUMAN; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0034760591     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.127.11.1319     Document Type: Article

References (13)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics. Cancer J Clinicians. 1998; 48:6-29.
2. Suen JY, Myers EN. Head and Neck Cancer. New York, NY: Churchill Livingston lnc; 1981.
3. Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin 2: identification of the antigens mediating response. Ann Surg. 1998;228:307-319.
4. Whiteside TL, Letessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993; 53:5654-5662.
5. Cortesina G, De Stefani A, Majore L, et al. Loco-regional treatment with low and high doses of interleukin 2 of head and neck squamous cell carcinoma recurrences [in Italian]. Acta Otorhinolaryngol Ital. 1994;14:3-9.
6. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 1994;153:1697-1706.
7. Brunda MJ, Gately MK. Antitumor activity of interleukin 12. Clin Immunol. 1994; 71:253-255.
8. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
9. Myers JN, Mank-Seymour A, Zitvogel L, et al. Interleukin 12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope. 1998;108:261-268.
10. Vitolo D, Letessier EM, Johnson JT, et al. Immunologic effector cells in head and neck cancer. J Natl Cancer Inst Monogr. 1992;13:203-208.
11. Cortesina G, Sacchi M, Galeazzi E, et al. Immunology of head and neck cancer: perspectives. Head Neck. 1993;15:74-77.
12. Cortesina G, De Stefani A, Sacchi M, et al. Immunomodulation therapy for squamous cell carcinoma of the head and neck. Head Neck. 1993;15:266-270.
13. Mickel RA, Kessler DJ, Taylor JM, et al. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Cancer Res 1988;48:5017-5022.